Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

Related Keywords

Germany ,Australia ,United States ,America ,Daniel Wolff ,National Institutes Of Health ,University Hospital Of Regensburg ,University Hospital ,Plenary Session ,National Institutes ,North America ,Middle East ,Lee Symptom Scale ,